Next Century Growth Investors LLC Sells 106 Shares of DexCom, Inc. (NASDAQ:DXCM)

Next Century Growth Investors LLC reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,698 shares of the medical device company’s stock after selling 106 shares during the quarter. Next Century Growth Investors LLC’s holdings in DexCom were worth $1,152,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Ameritas Investment Company LLC bought a new stake in DexCom during the 1st quarter valued at $27,000. Arkadios Wealth Advisors raised its holdings in DexCom by 58.5% during the 2nd quarter. Arkadios Wealth Advisors now owns 65 shares of the medical device company’s stock valued at $27,000 after buying an additional 24 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in DexCom by 140.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 65 shares of the medical device company’s stock valued at $28,000 after buying an additional 38 shares during the last quarter. CX Institutional raised its holdings in DexCom by 155.6% in the 2nd quarter. CX Institutional now owns 69 shares of the medical device company’s stock worth $29,000 after purchasing an additional 42 shares in the last quarter. Finally, Meridian Wealth Partners LLC raised its holdings in DexCom by 58.3% in the 1st quarter. Meridian Wealth Partners LLC now owns 95 shares of the medical device company’s stock worth $34,000 after purchasing an additional 35 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

In related news, SVP Sumi Shrishrimal sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 16th. The shares were sold at an average price of $450.00, for a total value of $180,000.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Chad Patterson sold 291 shares of the firm’s stock in a transaction that occurred on Thursday, September 9th. The stock was sold at an average price of $541.37, for a total transaction of $157,538.67. The disclosure for this sale can be found here. Insiders have sold a total of 43,766 shares of company stock worth $22,883,487 over the last three months. 0.52% of the stock is currently owned by insiders.

Several research analysts have commented on the stock. Piper Sandler upped their price objective on shares of DexCom from $550.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, September 16th. Citigroup upped their price objective on shares of DexCom from $530.00 to $630.00 and gave the stock a “buy” rating in a report on Friday, October 1st. Stephens upped their price objective on shares of DexCom from $468.00 to $546.00 and gave the stock an “overweight” rating in a report on Friday, July 30th. Raymond James upped their price objective on shares of DexCom from $466.00 to $515.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. They noted that the move was a valuation call. Finally, Morgan Stanley upped their price objective on shares of DexCom from $410.00 to $510.00 and gave the stock an “equal weight” rating in a report on Monday, August 2nd. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $515.13.

DXCM stock traded up $10.89 during trading on Thursday, hitting $558.94. 7,105 shares of the stock traded hands, compared to its average volume of 743,023. DexCom, Inc. has a 1 year low of $305.63 and a 1 year high of $579.00. The firm’s 50 day moving average is $533.80 and its two-hundred day moving average is $448.21. The stock has a market cap of $54.08 billion, a price-to-earnings ratio of 104.39, a price-to-earnings-growth ratio of 14.59 and a beta of 0.77. The company has a debt-to-equity ratio of 0.86, a current ratio of 5.78 and a quick ratio of 5.25.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 29th. The medical device company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.33. DexCom had a net margin of 24.45% and a return on equity of 16.17%. The company had revenue of $595.10 million for the quarter, compared to the consensus estimate of $548.02 million. As a group, analysts anticipate that DexCom, Inc. will post 2.46 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

See Also: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.